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Abstract
Background This is a qualitative study designed to examine
patient acceptability of re-sampling surgery for glioblastoma
multiforme (GBM) electively post-therapy or at asymptomatic
relapse.
Methods Thirty patients were selected using the conve-
nience sampling method and interviewed. Patients were
presented with hypothetical scenarios including a sce-
nario in which the surgery was offered to them routine-
ly and a scenario in which the surgery was in a clinical
trial.
Results The results of the study suggest that about two
thirds of the patients offered the surgery on a routine
basis would be interested, and half of the patients would
agree to the surgery as part of a clinical trial. Several
overarching themes emerged, some of which include:
patients expressed ethical concerns about offering finan-
cial incentives or compensation to the patients or sur-
geons involved in the study; patients were concerned
about appropriate communication and full disclosure
about the procedures involved, the legalities of tumor
ownership and the use of the tumor post-surgery;
patients may feel alone or vulnerable when they are
approached about the surgery; patients and their families
expressed immense trust in their surgeon and indicated
that this trust is a major determinant of their agreeing to
surgery.
Conclusion The overall positive response to re-sampling
surgery suggests that this procedure, if designed with all
the ethical concerns attended to, would be welcomed by
most patients. This approach of asking patients before-
hand if a treatment innovation is acceptable would ap-
pear to be more practical and ethically desirable than
previous practice.
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Introduction
The treatment of glioblastoma multiforme (GBM) typi-
cally involves a multimodal intervention consisting of a
craniotomy for tumor resection and radiotherapy with
concomitant and adjuvant chemotherapy with temozolo-
mide (TMZ). Despite the currently available regimens,
therapeutic resistance remains one of the major chal-
lenges [4]. It would be advantageous for neuro-
oncologists to explore other feasible personalized treat-
ment options that may enable clinicians to improve
patient outcomes.
There is emerging evidence that recurrent neoplasia,
as a result of clonal evolution, is often distinct geneti-
cally from the disease at diagnosis, and we cannot
expect treatment decisions to be made upon the initial
diagnostic sample to guide effective therapy throughout
the course of the disease. In particular, use of the
standard of care agent, temozolomide, is associated with
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a marked increase in the numbers of mutational events,
suggesting that the very therapy that contributes to
improved survival also leads to a mutationally more
complex disease at progression. In order to understand
the key genomic changes and possible distinct therapeu-
tic targets at the time of recurrence, we must obtain a
sample of the patient’s “new” disease, as the original
specimen is genetically out of date. This is routine for
patients with hematological malignancies where the risk
of bone marrow biopsy is low, but for glioblastoma
patients this would mean another craniotomy and/or
needle biopsy some time after treatment initiation and/
or at asymptomatic relapse [21]. This might be particu-
larly relevant for glioblastoma with recent demonstration
of several distinct molecular subtypes [22]. From a
clinical perspective, setting a standard of tumor re-
sampling as an essential measure of GBM evolution in
every patient would be paradigm shifting. Even though
current technical advances in neurosurgery make tumor
sampling acceptably low risk, it is imperative to ac-
knowledge not only the prospective long-term benefits
of undergoing tumor re-sampling, but also the potential
disadvantages [14].
Patients undergoing a repeat craniotomy for tumor re-
sampling post-treatment initiation and/or at asymptomatic
relapse may encounter the following problems: increased risk
of infection [1, 6, 8, 12, 15]; increased risk of neurological
deficits [5, 7, 10, 18]; increased risk of psychological compli-
cations such as depression [9, 16, 17]; additional normal living
time lost [13]; and a substantial increase in GBM treatment
cost [20].
Planned repeat surgery may have potential survival
benefits, and repeat sampling could facilitate a deeper
understanding of glioblastoma evolution and help to iden-
tify new potential treatment targets or readjust prognosis.
Although it is hypothesized that this strategy, in the long
run, will be essential to enable appropriate modification of
patient treatment to genetic/epigenetic clonal evolution, it
is important that we understand the short-term implications
as well. Because we are in the preliminary stages of
investigating this novel concept, there may exist ethical
and other challenges to performing a repeat surgery on
malignant brain tumor patients with no clinical indications,
as we currently define them.
In order to properly establish the parameters that will
enable clinicians to re-sample glioblastoma post-treatment
initiation and/or at asymptomatic recurrence, it is essential to
involve patients in helping us create ethically appropriate
standards for tumor re-sampling. We thus conducted a study
using qualitative methodology to gain insight into brain tumor
patients’ views about re-operation for molecular diagnosis.
The results of this study may determine whether there is a
“marketplace” for the use of routine post-treatment sampling
of glioblastomas, and more generically this approach may
represent a new paradigm for assessing whether patients are
open to new treatments before they are imposed upon them.
Methods
Study design
This study was conducted using qualitative research
methodology. Patients seen in consultation for malignant
glioma were interviewed using a semi-structured, open-
ended questionnaire (Appendix). All patients had at least
one surgery, and a number had two. Patients’ perceptions
regarding re-sampling of brain tumor post-therapy were
explored in detail.
Setting and participants
Participants were ambulatory patients recruited from a Neuro-
Oncology Clinic in a tertiary care academic hospital. This
clinic sees patients from three adult hospitals with neurosur-
gical services staffed by a total of about 25 neurosurgeons.
Patients who were: (1) <18 years of age, (2) aphasic, or (3) not
sufficiently cognitively intact and/or proficient in English
were excluded from the study.
Sample size
Thirty interviews were conducted on eligible and consented
patients. This sample size was selected because it was antic-
ipated that this number would be deemed sufficient in
attaining thematic saturation. Saturation in qualitative research
describes the point at which successive interviews will not
yield any new concepts or ideas beyond ones that have already
arisen [19].
Data collection
Open-ended, face-to-face interviews were conducted with
each participant by a single investigator with no clinical
relationship with the patients. A semi-structured interview
guide was used (see Appendix). Themes were freely explored
as they emerged. All interviews were digitally audio-recorded
and transcribed. Demographic parameters including age, sex,
religion, marital status, education, and occupation were col-
lected, as well as clinical data such as specific diagnosis and
date(s) of surgery.
Data analysis
Interviews were examined throughmodified thematic analysis
involving open and axial coding [19]. Open coding involves
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breaking down information into common groupings based on
shared ideas, whereas axial coding involves organizing infor-
mation according to overarching themes.
Research ethics
Participation was entirely voluntary, and informed consent
was obtained from all participants. Both the confidentiality
of patients and their freedom to withdraw from the study at
any time was explained andmaintained. The study was passed
by the Research Ethics Board of the University Health
Network.
Results
Demographic information on the 30 interviewed patients
is included in Table 1. Their responses were analyzed,
and the resulting data were organized into several
themes. Table 2 presents some of the most commonly
asked questions by patients. The themes that emerged are
presented below.
The major reason that patients were willing to undergo
the surgery is their surgeon
All of the patients indicated that they would only agree to
the surgery if they have faith in the skill level, experience,
and credentials of the surgeon. Many patients specified
that they would only undergo the surgery again if they
had the same surgeon as for their first surgery. Several
patients also required trust in the intentions of the sur-
geon. Patients feel that an ethical concern could arise if
the surgeon is in a position to exploit a patient’s trust in
order to increase their own credentials and/or acquire a
new publication. If they feel that the surgeon has their
best interests at heart, they are more comfortable going
forward with the surgery. Many patients would ask the
surgeon whether they would suggest the surgery to their
own family, accepting their response as a strong measure
of the validity of the surgery.
Time is an important but variable factor for patients,
depending mostly on patients’ requirement to take time
off work, time for recovery, and time to reintegrate
into their normal life
For patients who have to travel distances to come to the
hospital, and/or need to miss work or family time both in the
hospital and during the recovery phase, lost time was of
variable but often significant importance. Some patients felt
that the surgery was worth the extra time expenditure, while
Table 1 Patient
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others would find it to be a deterrent. Patients who are making
goals for the future and are asymptomatic are less interested in
surgery regardless of their prognosis.
The wish to be altruistic is very strong—this includes patients
who would not agree to the routine surgery but would agree
to participate in a trial
Some patients indicated that they would not be interested
in the operation if it were offered to them off study, fearing
the possible side effects and negative impact on their
quality of life. In spite of having such reservations, patients
agreed to a clinical trial for such a procedure. They indi-
cated that they believe in the benefits of the procedure even
though they might not want it for themselves. They hope
that their participation would result in better treatment for
others.
Experience during the first surgery and/or with previous
clinical trials is a major determinant of a patient’s willingness
to undergo a second surgery
Patients who had experienced complications during their first
surgery were reluctant to consider repeat surgery. Every pa-
tient who agreed to the second surgery had a relatively quick
recovery andminimal side effects. All patients except two said
prior complications would change their willingness to agree
dramatically, explaining that complications are a matter of
luck and can happen to anyone at any time. Feelings of trust
in clinical trials are elevated by positive previous experiences
with clinical trials.
Second surgery within 3 months of the first may be too
overwhelming for many patients
Some patients were willing and ready, while others stated that
they were just starting to come to terms with their diagnosis at
that time, and they are not ready to be approached about a
second surgery. The state of patient’s emotional well-being
determines their willingness to consider the surgery. Patients
mentioned the role of hope in their emotional well-being. A
second surgery and/or asymptomatic relapse reminds them
that there is a serious problem and reduces the feeling of hope.
Two patients would agree to the surgery because they felt that
their lives are effectively over, and wish to be altruistic and
“volunteer their brains.” This raises ethical issues because
some patients’ hopelessness may be inadvertently taken ad-
vantage of.
No matter what decisions they make, patients do not want
to sacrifice quality of life
Patients dread the possibility of their surgery causing them to
lose functionality and become dependent on their families.
Becoming a physical and financial burden provokes anxiety
and reluctance to agree to surgery. Patients give more weight
to family opinions in the case of the trial than they do in the
case of a surgery that is proven.
Overall, patients were generally interested in this surgery
Of the 30 patients interviewed during this study, 22 would be
interested in a routine GBM re-sampling biopsy should it be
offered, provided all ethical and patient comfort grounds
discussed above are addressed. Eight patients would not be
interested in the surgery for personal comfort purposes, al-
though all eight expressed support for the research. Sixteen
patients would agree to participate in a clinical trial for such a
procedure given that all ethical issues are addressed. Two
more patients indicated that they might be interested in a
clinical trial; however, it would depend strongly on their
Table 2 Most common questions patients asked
○ “How much are you cutting? What would the surgery actually look
like?”
○ “What is the likelihood of my quality of life staying the same?”
○ “What is the research supporting this biopsy?”
○ “What happens to the tumor after it is taken out?”
○ “What are the chances of me experiencing a complication during
surgery and/or dying during surgery?”
○ “Is this the best option right now? Are there better options? Are we
being open minded?”
○ “What are we hoping to achieve?”
○ “What is the healing time needed?”
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emotional and physical stability at the time. Twelve patients
would not be interested in participating in a clinical trial at all.
Some patients expect financial compensation if they have
to take time off work or travel for the treatment, while others
felt financial incentives might increase patient unintentional
participation
Financial incentive to the patient was a major ethical concern,
as it would increase the possibility of agreement to the surgery.
Conversely, patients felt it was unethical to expect a patient to
incur an extra financial burden to undergo a trial surgery at a
time when many are already financially strained. Patients also
expressed concerns about financial incentives to the surgeon
and/or researcher.
Complete communication as well as disclosure prior
to surgery was a major concern for most of the interviewed
patients
Patients expressed concerns about incomplete explanation of
the procedures. Patients would prefer to have a clearer picture
of the procedure before agreeing to it. Some patients are
interested in seeing the specific research behind the experi-
mental surgery. Patients also indicated that they would appre-
ciate this information being provided during the first diagnosis
or earlier in their treatment plan, allowing them to psycholog-
ically prepare for being asked about a second invasive proce-
dure. Some patients are interested in detailed explanation of
where/how their tumor will be handled and the legalities of
ownership of the tumor after resection.
The appointment where the patient is told about the surgery
is a very emotionally draining time, which may impact
their decision-making
Patients are often too shocked to take in information about the
procedures. Patients who feel that they have no other way to
survive may consent to the surgery because they are so wor-
ried about their diagnosis. In the case of an asymptomatic
relapse, the fact that there is a relapse of tumor in their brain is
the main thing that patients hear. They may not necessarily
comprehend the implications or prognostic significance of an
asymptomatic tumor. Shocked and desperate, patients feel that
they often agree to procedures without due analysis; they need
time to consider their options and choose wisely, such that
they do not regret their decisions post-surgery. In the inter-
views performed, there was a clear trend where patients who
initially agreed to the surgery and the trial very enthusiastical-
ly often became less enthusiastic as the interview progressed
and they were asked more specific questions about their
feelings. Some patients require more time to go home and
think about the situation in a more comfortable setting.
Discussion
When considering any surgery, patients must contemplate
several facts and weigh the pros and cons of the surgery before
making a decision. Surgery for re-sampling GBM represents a
surgical innovation [2]. Some factors patients considered re-
garding the acceptance of this innovation include: trust in their
surgeon, expenditure of time, financial burden to themselves
and their family, wish to be altruistic, psychological and
physical well-being, and their experience during the first
surgery. The participants also highlighted numerous ethical
concerns that they or other potential patients may have, and
that may result in patient reluctance to participate, including
financial incentives, lack of communication, exploitation of
patient vulnerability, and surgeon transparency.
From the results of this study, trust in one’s surgeon is
paramount and arguably the single most important factor in
a patient accepting such a surgery. The importance of trust has
not surprisingly been reported to be very important for pa-
tients participating in many other qualitative studies [3, 11].
Because this surgery would be a second or third surgery,
presumably the patient would have earned trust in his/her
surgeon, since they got the patient through it the first time.
Some concepts, such as re-sampling, are nuanced and com-
plex, while one’s trust in another human being, such as their
surgeon, is basic and may trump other factors. The process
will also be helped by the neuro-oncologist and radiation
oncologist being on board with the plan; these members of
the team will obviously have seen and gotten to know every
patient considered for re-sampling surgery.
It is important to ensure that the consent discussions and
documentation contain clear and understandable details about
the surgery. Some patients are interested in exactly what will
happen to their tumor post-surgery. This may be addressed by
including a section in the consent documents that specifies
who has rights and access to the tumor after resection and
what will happen to the extracted components.
Patients perceived a major ethical concern with the fact that
they often feel vulnerable and hopeless when they are told
about any surgery. At such a time, patients would appreciate
having a family member present to help interpret the situation
and to give support. It may also be beneficial to allow the
patient and their family whatever time they need to consider
all aspects of the surgery. Surgeons are used to immediate
results including getting consent the day surgery is suggested,
but while this is efficient, it may not work well for some.
Patients who are initially against the surgery may decide
otherwise once they feel more comfortable and familiar with
the procedure.
Another important consideration for the patients is the cost.
Some patients indicated that they are concerned about travel
costs, costs of parking, costs of staying in a hotel if they are
not from the city, lost earnings from taking time off of work,
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and other associated costs. Patients may appreciate some
compensation for such expenditures should they participate.
A major ethical concern that arises from monetary compensa-
tion is the distinction between compensation and monetary
incentives [23]. Patients felt an ethical dilemma may emerge
in that financial gain from participating in a trial may cloud
their judgment. Such factors should be considered when de-
signing the study as it might be onerous to request that patients
pay to travel to the hospital and stay at a hotel for a procedure
that may not be necessary; however, offering a patient mon-
etary incentives for surgery might cloud their judgment.
Similarly, financial incentives to the surgeon(s) or individuals
who are carrying out the study would result in major ethical
predicaments to patients. The most egregious breach of trust
would be for surgeons to advocate this (or any other) procedure
to patients in whom the surgery may be contraindicated, in which
case the most ethical way to do this surgery would be in the
context of a clinical trial until there is proven value of the proce-
dure. For these reasons, it is crucial that no special financial
incentives are given to surgeons in the trial. Some concerns were
expressed about how soon after the first surgery the re-sampling
surgery would be offered. Many patients felt that they would not
be psychologically prepared for a second surgery 3 months after
the first. They felt that because the time of diagnosis was so
chaotic, they did not have time to consider their situation and
mourn their diagnosis. At 3 months most patients had finished
their surgery, radiation, and chemotherapy. At this point they were
beginning to concede the reality of their situation. Patients who
had remained calm during the initial diagnosis stated that the
realization of what they had been through had just began to dawn
on them after 3 months, and at that point if they were asked to
undergo a biopsy, they would be psychologically devastated.
Some patients, however, had recovered completely within 3
months and were in adequate spirits to be prepared for a second
surgery. It is important to assess the emotional state of a patient
before asking them to participate in a trial, but it is not often
possible to determine exactly how a patient will react. Most
patients stated that they would be more comfortable considering
a second surgery 6 months after their first.
Patients’ previous experiences also inform their reaction to
being asked to participate in a trial surgery. Patients who had
participated in clinical trials in the past were more open to the
idea. Almost every patient stated that their experiences during
the first surgery would be a strong determinant of their will-
ingness to participate in a second surgery. This includes the
surgery itself, the recovery process, and their experience with
the hospital staff. Almost every patient stated that a compli-
cation during the first surgery would affect his or her willing-
ness to consider a second surgery. It is important to keep this
in mind when approaching patients about participating in a
trial.
Even with all of the concerns that patients expressed, most
were interested in a proven re-sampling surgery. Many patients
were also interested in the clinical trial testing the value of this
procedure. This study suggests that over two thirds of the pa-
tients would consider participating in a re-sampling surgery if it
were offered. It also suggests that about half of the patients
would consider participating in the clinical trial.
Limitations of this study
The patients sampled were from adult teaching hospitals in a
large academic health center in a socialized health care sys-
tem, being seen at one clinic. These results may not be
generalizable to other cities, countries, settings, and cultures.
Conclusion
It appears that most patients would be interested in resampling
surgery for glioblastoma post-therapy or at asymptomatic
relapse if it were offered routinely, and many would also be
interested in participating in a clinical trial.
Asking patients about the acceptability of a new interven-
tion before it becomes clinically available is not the standard
model in current-day health care delivery, but this approach
would seem to be logistically and ethically preferable. Finding
out whether a “marketplace” exists for new interventions may
represent a more responsible way to introduce much-needed
innovations in health care, as opposed to the current practice
of innovating, and then seeing if there is an application for the
innovation that is acceptable to patients.
Conflicts of interest None.
Funding Funding for this study was provided by the Lipton Fund (Dr.
Mark Bernstein fund holder).
Interview questionnaire
Preamble
This interview is intended to explore your perceptions regard-
ing re-sampling of malignant brain tumour post-therapy and/
or at non-symptomatic relapse and to discuss your experiences
about the treatments you have undergone so far. Your input is
important to us and will help us do a better job in
implementing such standards.
Interview proper
1. Please tell me about how you came to be diagnosed.
How did you feel, and what was your initial reaction
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when your neurosurgeon first diagnosed you with a
malignant brain tumour and told you that you needed
to have surgery? How were you feeling after that ap-
pointment? Tell me more about your experience.
2. We understand that since the discovery of your tumour, it
has most likely been a stressful and exhausting time for
both you and your family. How have you and your
family been coping since? Have you been able to cope
well, or have you encountered difficulties along the
way?What type(s) of copingmechanisms have you been
trying to use to help you through this? Tell me more
about it.
3. Your team of doctors has told you about the risks and
possible complications associated with brain surgery.
Specifically, there is risk of infection, post-operative
neurological deficits like speech problems, are or leg
weakness, and others. How did you feel when you were
being told about these risks? How do you feel about
these risks themselves? Are you worried that these
things will happen to you? Do you feel scared and/or
nervous? Tell me more.
4. What are your thoughts about the brain tumour you
currently have? Has this diagnosis affected your feelings
about yourself and your attitudes towards life? What
short-term and/or long-term goals do you have in life?
Tell me more about it.
5. Malignant brain tumours are usually treated with a mul-
tiple different treatments and typically involve surgery,
radiotherapy, and chemotherapy.What are your thoughts
on this, and how do you feel about having to go through
these steps? Tell me about it.
6. HYPOTHETICAL CASE SCENARIO: You have been
diagnosed with a glioblastoma (a serious malignant
brain tumour with a poor prognosis) and have under-
gone your first craniotomy for tumour resection about a
month ago. Doctors were able to remove part of your
tumour, and you are currently undergoing radiotherapy
and chemotherapy. You visited your neurosurgeon for a
follow-up yesterday afternoon, and he mentions about
doing another surgery for you that may help understand
your tumour and maybe improve your chances for
survival.
How do you feel about this? Would you feel eager or
reluctant about such an idea? If reluctance is what you
feel, why do you think you feel that? Do you think the
experiences you had during your last surgery would
affect your decision in agreeing to the second surgery?
What questions and/or concerns would you express to
your doctor at this point?
7. HYPOTHETICALCASE SCENARIO: This is a follow-
up to the other scenario. Your neurosurgeon informs you
about a medical research initiative that may potentially
enable doctors to better enhance treatment for brain
tumour patients like you. To reach this goal, scientists
need to examine, identify, and characterize cancerous
cells – those of which we would obtain from the patients.
This may or may not benefit you directly, but to have your
chances of being benefitted slightly increased, your neu-
rosurgeon must re-operate on you to collect another
sample of your initial/recurrent tumour.
How would you feel about this? Do you believe an
ethical concern has emerged if your doctor recommends
you to have surgery again under these circumstances?
Would you feel comfortable and proceed with this inter-
vention, or would you feel hesitant and doubtful about
it? Alternatively, would you feel obligated to listen to the
doctor's instructions because you feel that he or she
knows what's best for you (despite your reluctance in
doing a second surgery)? Please tell me about your
thoughts on this.
8. If you were recommended by your clinician to undergo a
repeat surgery (for tumour re-sampling) within 3 months
of treatment initiation or at relapse – an operation that
could potentially assist him or her in planning for a more
effective therapy for you – would you feel comfortable
to go ahead with this procedure? Note that it is important
to consider the risks of surgery as well. Also, with the
restriction of the procedure being done within 3 months
of your first surgery – would this be too overwhelming
for you? How would you feel? What are the thoughts
that come to mind?
9. If you had experienced complications from your initial
surgery, and your neurosurgeon suggests you to undergo
a repeat surgery (for the same reasons as listed in the
previous question), would you agree to do it? Why or
why not? Please explain, and tell me more about it.
10. What is your attitude regarding treatment for your diag-
nosis? Of course, it is expected of you to adhere to the
treatment(s) you're required to undergo – after all, your
goal is to get better. This process would typically involve
several visits to your doctors and require you to spend a
fair bit of time at the hospital. If you were to undergo a
repeat craniotomy for tumour re-sampling post treatment
initiation or at relapse, for instance, you would be re-
quired to spend additional time at the hospital. Having
said this, we completely understand that you would like
to spend more time with family and friends during this
difficult period in your life, and because this aspect is
important for many people. How willing would you
would be to dedicate your time towards experimental
medical procedures that may or may not ultimately
benefit you. Tell me your thoughts on this.
11. Similar to the bone marrow sampling that doctors do
with leukemia patients, we would like to re-sample
cancerous brain tumours to gaining a better understand-
ing on glioblastoma evolution with Temozolomide (the
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chemotherapeutic drug) as well as identifying genetic
drivers within a patient's tumour. Ultimately, our goals
are to improve patient prognosis, enhance the efficacy of
conventional therapies, and to create newly combined
treatments that will potentially make patient cancer re-
missions and cures a more durable process. MRI scans
provide only crude information about patients' situa-
tions, and we believe that studying tumour genes will
allow us to improve the effectives of our current thera-
pies. In order to obtain these brain tumour samples,
however, you would need to go for surgery again. Do
you think it is ethical to subject patients to repeat sam-
pling after initial treatment? Tell me how you feel about
this. Do you feel that going through a procedure like this
for the second time will psychologically affect you in
any way? How do you think this may affect your family
and loved ones? Please explain, tell me more.
12. Is there anything else you would like to add regarding
what we just talked about, or in general?
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
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Comment
This is definitely a very interesting study, although rather uncommon in
the neurosurgical literature. Authors disclose very clearly feelings accom-
panying the decision to undergo a neurosurgical intervention, especially
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emotions associated to the perception of a surgical procedure with uncer-
tain results. Above all, Authors were able to disclose, with surprising
clarity, feelings that shake the individual who is faced with cancer and the
fear of the death. Anxiety, trust, suspicion, doubt, altruism, sense of
inadequacy, among other emotions, emerge clearly from this study. These
feelings, like all emotional experiences, are very human and universal. I
agree with Authors that the cultural context may influence the propensity
to accept a neurosurgical procedure as part of an experimental protocol.
Nonetheless, I believe that the importance of this study relies in helping us
to better understand the human and universal emotions that accompany
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